Deep Tech Startups

Aika is an operating system that uses AI and automation to orchestrate clinical trial development end-to-end, helping organizations accelerate protocol creation, prevent amendments, and interpret complex datasets across all stages of trial development.

3 investors

Blackrock Neurotech develops a neurotechnology platform, including brain-computer interface systems, aimed at improving patient lives and treating neurological conditions. It builds implantable neural interface technology for medical and research applications.

3 investors

Bliq develops autonomous driving technology to make private cars driverless. The company is building self-driving mobility solutions for European cities.

3 investors

Bloom Science is a clinical-stage biotech company developing live biotherapeutic products that replicate the effects of the ketogenic diet through the gut-brain axis. Its lead program, BL-001, targets obesity and Dravet syndrome, supported by the IrisRx discovery platform that uses gut commensal microbes and synthetic biology to develop therapies for metabolic and neurological disorders.

3 investors

Boltz develops generative AI models for biomolecular design and drug discovery, used by researchers across pharmaceutical, biotech, agricultural, and academic sectors. The company offers frontier foundation models for protein and small-molecule design through an API with enterprise deployment options.

3 investors

BreezeBio develops a programmable delivery platform called NanoGalaxy for targeted delivery of genetic medicines to specific cells and tissues. The platform addresses the challenge of enabling genetic payloads to reach their target sites in the body to control biological processes.

3 investors

BrightSpec develops molecular rotational resonance (MRR) spectroscopy instruments and software that identify and quantify gas-phase molecules from complex mixtures without front-end separation. Its analytical platforms serve the pharmaceutical, chemical, and consumer goods industries for tasks such as structure validation, residual analysis, and raw material characterization.

3 investors

Brineworks develops an electrochemical Direct Air Capture system that uses electrolyzer technology and renewably powered intermittent operation to capture CO₂ at low cost. Its CO₂ is aimed at e-fuel producers (e-SAF, e-NG, e-Methanol), carbon dioxide removal, and other CCUS applications.

3 investors

C-Infinity builds foundational AI for mechanical design and manufacturing that reasons about 3D geometry, motion, spatial constraints, and production logic. Its product, AutoAssembler, connects to CAD and PLM systems to automate assembly process planning, ECO reviews, and generate production-ready assembly instructions for engineering and manufacturing teams.

3 investors

Caelus is a chip design company that develops high-performance ADC/DAC integrated circuits, including high-precision SAR ADCs and high-speed ADCs, using its own patented technology. Its products serve industries such as industrial automation, energy, instrumentation and measurement, data acquisition, communications, and medical imaging.

3 investors

Calectra develops electrified, high-temperature industrial heat systems designed to reduce costs and emissions for industrial applications. The company serves energy-intensive manufacturing and industrial sectors requiring decarbonized thermal solutions.

3 investors

Cambium develops high-performance advanced materials—including thermal protection systems, high-temperature structural polymers, and laser/directed-energy protection—for extreme-environment applications across aerospace, space, defense, and industrial markets. It uses AI-driven molecular design and domestic agile manufacturing to develop and deliver materials faster, and has acquired advanced composite prepreg manufacturer SHD Group.

3 investors

Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria. Its pipeline includes a first-in-class mitophagy agonist intended for therapeutic use in aging- and disease-related conditions.

3 investors

Caracol develops large-scale additive manufacturing technology for industrial production, enabling companies in aerospace, automotive, architecture, marine, and railway sectors to produce advanced components more efficiently and sustainably. The company provides integrated turnkey solutions that enhance manufacturing flexibility, cost-effectiveness, and environmental performance.

3 investors

Cascade Biocatalysts develops engineered biocatalysts designed to be more cost efficient, reusable, and longer-lasting with a wider operating window and higher output. The company positions its biocatalysts as offering improved performance for industrial chemical and biological processes.

3 investors

Casma Therapeutics develops therapies based on targeted autophagy, using its PHLYT (Phagosome-Lysosome Targeting) platform to initiate target-specific degradation of disease-causing cellular components regardless of size or complexity. The company aims to treat diseases that current drugs have not been able to target.

3 investors

Catalyx builds standardized infrastructure for deploying sensor payloads into orbit, offering common power, thermal, and data interfaces along with continuous monitoring and real-time data transmission. The product targets space operators seeking faster, lower-cost payload deployment.

3 investors

Catena develops a conjugation platform for antibody-drug conjugates (ADCs) and multi-payload conjugates used in oncology for solid tumors. The company's technology enables therapeutic structures that deliver dual payloads to cancer targets.

3 investors

Cavalry Biosciences is a biopharmaceutical company focused on developing medicines that leverage the body's inherent regenerative and repair mechanisms, particularly in areas of age-related disease and tissue regeneration. The company applies translational biology and drug development expertise across multiple therapeutic areas.

3 investors

Cellply develops VivaCyte, an automated analytical platform for characterizing immune cells at single-cell resolution, used in the discovery and process development of cell therapies. The system handles sample preparation through image processing, analyzing over 100 samples per run and more than 1,000 single cells per sample.

3 investors

Cerabyte develops long-term, sustainable data storage technology aimed at preserving digital records permanently. It positions itself as an archival data storage company.

3 investors

ChemFinity develops advanced chemical separation technologies for recovering critical minerals and other resources. The company aims to support a more secure domestic supply of these materials.

3 investors

ChemT builds CelMo, an AI-driven virtual cell platform that models cell states and predicts responses to process, genetic, and molecular changes to optimize biomanufacturing. It applies this to CHO cells for antibody/protein production and T cell therapy manufacturing (including its Chemplify small molecule), serving biopharma teams working on cell line and process development.

3 investors

ChrysaLabs provides soil carbon measurement, reporting, and verification (MRV) using patented direct-contact proximal sensing technology deployed in field soil. Its solution generates Verra VM0042/VCS-aligned carbon sequestration data for developers of soil carbon credit projects, aiming to produce lower-cost, bankable carbon assets.

3 investors